Treatment of peripheral diabetic neuropathy in Zucker diabetic fatty (ZDF) rats with cariporide

Sergey Lupachyk1,2, Hanna Shevalye1,2, Pierre Watcho1, Alexander Obrosov1,2, Irina G. Obrosova1, Mark A. Yorek2*

1Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, USA
2Department of Veterans Affairs Iowa City Health Care System and Department of Internal Medicine, University of Iowa, Iowa City, USA; *Corresponding Author: mark-yorek@uiowa.edu

Received 23 January 2014; revised 15 February 2014; accepted 22 February 2014

Copyright © 2014 Sergey Lupachyk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In accordance of the Creative Commons Attribution License all Copyrights © 2014 are reserved for SCIRP and the owner of the intellectual property Sergey Lupachyk et al. All Copyright © 2014 are guarded by law and by SCIRP as a guardian.

ABSTRACT

To determine the effect of Na+/H+-exchanger-1 on diabetic neuropathy in Type 2 diabetes Zucker diabetic fatty (ZDF) rats and lean controls were treated with cariporide (10 or 20 mg/kg/d), a Na+/H+-exchanger-1 inhibitor, for 4 weeks at 15 weeks of age. Neuropathy endpoints included motor (MNCV) and sensory (SNCV) nerve conduction velocities, thermal nociception, tactile allodynia and intraepidermal nerve fiber density. Advanced glycation endproduct and markers of oxidative stress including nitrated protein levels in sciatic nerve and dorsal root ganglion were also evaluated. Expression of Na+/H+-exchanger-1 in dorsal root ganglion neurons was increased in ZDF rats. At 15 weeks of age ZDF rats displayed hyperglycemia, MNCV and SNCV deficits, thermal hypoalgesia and tactile allodynia. At 20 but not 10 mg/kg/d, cariporide significantly improved MNCV and SNCV deficits, thermal hypoalgesia and tactile allodynia. Cariporide treatment was also associated with reduction of diabetes-induced accumulation of advanced glycation end-product (AGE), oxidative stress and nitrated proteins in sciatic nerve and dorsal root ganglion neurons. In conclusion, these findings support an important role for Na+/H+-exchanger-1 in peripheral diabetic neuropathy, and provide rationale for development of Na+/H+-exchanger-1 inhibitors for treatment of diabetic neural complications.

KEYWORDS

Diabetic Neuropathy; Sodium/Hydrogen Exchanges; Oxidative Stress

1. INTRODUCTION

After many years of research the only recommended treatment for diabetic peripheral neuropathy is good glycemic control [1]. Hyperglycemia is a major contributing factor to the pathology of diabetic complications but the intracellular metabolic pathways linking excess glucose to peripheral nerve injury are not completely understood making identification of effective treatments based on metabolic dysfunction difficult [2-5]. A consequence of hyperglycemia that has attracted our interest is that inhibition or insufficient activation of the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase associated with diabetes underlies diversion of excessive glycolytic flux towards the formation of methylglyoxal and α-glycerophosphate [6-10]. This, in turn, has been shown to lead to 1) a decrease in free cytosolic NAD+/NADH ratio and resulting activation of the superoxide-generating enzyme, NAD(P)H oxidase, and 2) a formation of advanced glycation end-products that generate free radicals during interaction with their receptors [11-13]. The mechanism(s) underlying diabetes-associated activation of the upper part of glycolysis remain unidentified. One mechanism we have been investigating is the activation of Na+/H+-exchanger-1 [10]. Na+/H+-exchanger-1 is ubiquitously distributed in mammalian tissues and plays an important role in regulation of intracellular pH by removing protons that are continuously generated in normal cells [14-20]. Several reports suggest that upregulation of Na+/H+-exchanger-1 activity, recently demonstrated in several tissue-sites for diabetes complications, leads to an increase in cytosolic pH and consequent activation of glucose transport and all enzymes in...
the upper part of glycolysis, especially, phosphofructokinase [21-23]. We have recently demonstrated in a rat model of Type 1 diabetes that increased expression/activation of Na+/H+-exchanger-1 may lead to an increase in the formation of advanced glycation end-products that contributed to an increase in oxidative stress and development of peripheral diabetic neuropathy, which was prevented by inhibition of Na+/H+-exchanger-1 [10]. To test the universality of this finding we have performed a similar set of experiments using Zucker diabetic fatty (ZDF) rats as a model of Type 2 diabetes.

2. MATERIALS AND METHODS

Materials: Unless stated otherwise all chemicals used in these studies were obtained from Sigma Chemical Co. (St. Louis, MO).

Animals: The experiments were performed in accordance with regulations by the National Institutes of Health Principles of Laboratory Animal Care, and the Pennington Biomedical Research Center. Male ZDF and lean littermate controls were purchased from Charles River, (Wilmington, MA) at 6 weeks of age. Both ZDF rats and lean littermates were fed a high fat diet (Harland 7013) as described by Charles River and had access to water ad libitum. After 15 weeks rats were divided into six experimental groups; control and diabetic rats were treated with or without cariporide, Na+/H+-exchanger-1 inhibitor, (10 or 20 mg/kg/day in the drinking water) for 4 weeks [18].

Behavioral tests: The paw withdrawal latency in response to radiant heat was recorded at a 15% intensity (heating rate of ~ 1.3 °C/sec) with a cutoff time of 30 sec using the IITC model 336 TG combination tail-flick and paw algesia meter (IITC Life Sciences, Woodland Hills, CA) [24]. Tactile responses were evaluated by quantifying the withdrawal threshold of the hindpaw in response to stimulation with flexible von Frey filaments as previously described [25]. The data were reported in sec and grams, respectively.

Physiological tests: On the day of terminal studies rats were weighed and anesthetized with Nembutal i.p. (50 mg/kg, i.p., Abbott Laboratories, North Chicago, IL). Non-fasting blood glucose was determined. Sciatic motor nerve conduction velocity and digital sensory nerve conduction velocity were measured as previously described [26]. The data were reported in meters per second.

Intraepidermal nerve fiber density: Footpads were fixed in ice-cold Zamboni’s fixative for 3 h, washed in 100 mM phosphate-buffered saline (PBS) overnight, and then in PBS containing increasing amounts of sucrose i.e., 10%, 15%, and 20%, 3 h in each solution. After washing, the samples were snap frozen in O.C.T. and stored at ~80°C. Three longitudinal 50 μm-thick footpad sections were cut using a Leica CM1950 cryostat (Leica Microsystems, Nussloch, Germany). At this point immunohistochemistry analysis of nerve fibers were examined as previously described [10,26].

Western blot analysis of methylglyoxal-derived AGE in rat sciatic nerve: To assess methylglyoxal-derived AGE expression by Western blot analysis, sciatic nerve segments (~ 20 mg) were placed on ice in 200 μl of radiimmunoprecipitation assay buffer (RIPA) containing 50 mmol/l Tris-HCl, pH 7.2; 150 mmol/l NaCl; 0.1% sodium dodecyl sulfate; 1% NP-40; 5 mmol/l EDTA; 1 mmol/l EGTA; 1% sodium deoxycholate and the protease/phosphatase inhibitors leupeptin (10 μg/ml), pepstatin (1 μg/ml), aprotinin (20 μg/ml), benzamidine (10 mmol/l), phenylmethylsulfonyl fluoride (1 mmol/l), sodium orthovanadate (1 mmol/l), and homogenized on ice [10]. The homogenates were sonicated and centrifuged at 14,000 g for 20 min. The lysates (40 μg protein) were mixed with equal volumes of 2x sample-loading buffer containing 62.5 mmol/l Tris-HCl, pH 6.8; 2% sodium dodecyl sulfate; 5% β-mercaptoethanol; 10% glycerol and 0.025% bromophenol blue, and fractionated in 5%-20% SDS-PAGE in an electrophoresis cell (Mini-Protein III; Bio-Rad Laboratories, Richmond, CA). Electrophoresis was conducted at 15 mA constant current for stacking, and at 35 mA for protein separation. Gel contents were electrotransferred (80 V, 2 h) to nitrocellulose membranes using Mini Trans-Blot cell (Bio-Rad Laboratories, Richmond, CA) and western transfer buffer (25 mmol/l Tris-HCl, pH 8.3; 192 mmol/l glycine; and 20% (v/v) methanol). Free binding sites were blocked in 5% (w/v) BSA (methylglyoxal-derived AGE) diluted in 20 mmol/l Tris-HCl buffer, pH 7.5, containing 150 mmol/l NaCl and 0.1% Tween 20, for 1 h. After blocking free binding sites, primary antibodies to methylglyoxal-derived AGE (Trans Genic Inc., Kumamoto, Japan) were applied overnight, at 4°C. Then the anti-mouse secondary antibody was applied at room temperature for 1 h. Protein bands detected by the antibodies were visualized with Amersham ECL™ Western Blotting Detection Reagent (Little Chalfont, Buckinghamshire, UK). Afterwards, the membranes were stripped and reprobed with β-actin antibody to confirm equal protein loading. Stripping was conducted in 25 mmol/l glycine-HCl, pH 2.5 buffer containing 2% SDS. The data were quantified by densitometry (Quantity One 4.5.0 software, Bio-Rad Laboratories, Richmond, CA).

ELISA measurements of 4-hydroxynonenal adducts and nitrotyrosine in rat sciatic nerve: For 4-hydroxynonenal adduct measurements, the samples were homogenized in 20 mmol PBS, pH 7.4 (1:10, w/v), on ice [10]. Homogenates were centrifuged at 14,000 g (4°C, 20 min). Supernatants were used for measurements of 4-hydroxynonenal adducts with the OxiSelect™ HNE-His Adduct
ELISA kit (Cell BioLabs, Inc., San Diego, CA). For nitrotyrosine measurements, the samples were homogenized on ice in RIPA buffer (1:10 w/v) containing 50 mmol/l Tris-HCl, pH 7.2; 150 mmol/l NaCl; 0.1% sodium dodecyl sulfate; 1% NP-40; 5 mmol/l EDTA; 1 mmol/l EGTA; 1% sodium deoxycholate; and containing the protease/phosphatase inhibitors leupeptin (10 μg/ml); aprotinin (20 μg/ml); benzamidine (10 mmol/l); phenylmethylsulfonyl fluoride (1 mmol/l); and sodium orthovanadate (1 mmol/l). Homogenates were sonicated (3 × 5 s) and centrifuged at 14,000g (4°C, 20 min). Supernatants were used for measurements of nitrotyrosine concentrations with the OxiSelect Nitrotyrosine ELISA kit (Cell Biolabs, Inc., San Diego, CA). 4-HNE adducts and nitrotyrosine concentrations were normalized per milligram of protein. Protein was measured with the bicinchoninic acid protein assay (Pierce Biotechnology, Rockford, IL).

Fluorescent immunohistochemistry in dorsal root ganglia: Dorsal root ganglia were dissected and fixed in normal buffered 4% formaldehyde for 24 h at 4°C, dehydrated and embedded in paraffin [10]. Analysis of nitrotyrosine and Na+/H+-exchanger-1 levels was conducted as previously described [10]. Nitrotyrosine and Na+/H+-exchanger-1 fluorescence intensity of individual DRG neurons was quantified using the ImageJ software (National Institutes of Health), and normalized per neuronal area. For nitrotyrosine immunofluorescence analysis, nuclei of individual cells were excluded from the regions of interest. Neurons (10 - 28 per rat) were counted, and the average values for each animal were used to calculate group means. Fluorescence intensity was expressed as mean ± SEM for each experimental group.

Statistical analysis: The results are presented as mean ± S.E.M. Data were subjected to equality of variance F test and then to log transformation, if necessary before one-way analysis of variance. Where overall significance (p < 0.05) was attained, individual between-group comparisons for multiple groups were made using the Student-Newman-Keuls multiple-range test. When between-group variance differences could not be normalized by log transformation (datasets for body weights and plasma glucose), the data were analyzed by the nonparametric Kruskal-Wallis one-way analysis of variance, followed by the Bonferroni/Dunn test for multiple comparisons. Individual pair-wise comparisons in Table 1 were made using the unpaired two-tailed Student t test. Significance was defined at p < 0.05.

3. RESULTS

Baseline changes in ZDF rats prior to treatment. ZDF rats spontaneously become hyperglycemic at about 6 - 8 weeks of age [27,28]. For these studies cariporide treat-

<table>
<thead>
<tr>
<th>Determination</th>
<th>Control (12)</th>
<th>ZDF (12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood glucose (mM)</td>
<td>6.2 ± 0.1</td>
<td>22.7 ± 0.4*</td>
</tr>
<tr>
<td>Thermal response latency (sec)</td>
<td>10.9 ± 0.6</td>
<td>17.0 ± 0.5*</td>
</tr>
<tr>
<td>Tactile response threshold (g)</td>
<td>14.4 ± 1.6</td>
<td>7.2 ± 2.1*</td>
</tr>
<tr>
<td>Intraepidermal nerve fiber density</td>
<td>22.5 ± 1.3</td>
<td>16.7 ± 0.7*</td>
</tr>
<tr>
<td>(profiles/mm)</td>
<td>55.9 ± 1.4</td>
<td>50.0 ± 1.9*</td>
</tr>
<tr>
<td>MNCV (m/sec)</td>
<td>36.9 ± 0.9</td>
<td>33.3 ± 0.6*</td>
</tr>
</tbody>
</table>

Zucker diabetic fatty (ZDF) rats and age matched ZDF lean (control) rats were examined at 15 weeks of age. Data are presented as the mean ± SEM. *p < 0.05 compared to control. Number in parentheses indicates the number of experimental animals.

ZD 61

Effect of treatment of ZDF rats with cariporide on body weight and blood glucose. Data in Table 2 demonstrate that treating ZDF or lean rats for 4 weeks with 10 or 20 mg/kg/day cariporide, an inhibitor of Na+/H+-exchanger-1, did not significantly affect weight gain or hyperglycemia.

Effect of treatment of ZDF rats with cariporide on neural complications. Data in Table 2 demonstrate that 4 weeks of treatment with 10 mg/kg/day cariporide significantly improved motor nerve conduction velocity but not sensory nerve conduction velocity, thermal response latency or tactile response threshold compared to untreated ZDF rats. However, when the dose of cariporide was increased to 20 mg/kg/day motor and sensory nerve conduction velocity, thermal response latency and tactile response threshold were all significantly improved compared to untreated ZDF rats. Data in Figure 1 demonstrate that treating ZDF rats for 4 weeks with 20 mg/kg/day cariporide stimulated recovery of intraepidermal nerve fibers in the hindpaw. Treatment of lean rats with 10 or 20 mg/kg/day cariporide for 4 weeks did not affect neural endpoints.

Effect of treatment of ZDF rats with cariporide on advanced glycation end-products, nitrated proteins and 4-hydroxynonenal in sciatic nerve. Data in Figure 2 demonstrate that methylglyoxal-derived advanced glycation end-products are significantly increased in the sciatic nerve of ZDF rats. Treating ZDF rats for 4 weeks with 20 mg/kg/day cariporide significantly reduced these protein markers associated with advanced glycation end-product accumulation. Data in Table 3 demonstrate that
Table 2. Body weight, blood glucose, motor and sensory nerve conduction velocity, thermal algesia and tactile response in lean and ZDF rats treated with or without cariporide for 4 weeks.

<table>
<thead>
<tr>
<th>Determination</th>
<th>Control (12)</th>
<th>Control + 10 cariporide (12)</th>
<th>Control + 20 cariporide (12)</th>
<th>ZDF (12)</th>
<th>ZDF + 10 cariporide (12)</th>
<th>ZDF + 20 cariporide (12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final weight (g)</td>
<td>381 ± 4</td>
<td>370 ± 8</td>
<td>374 ± 5</td>
<td>402 ± 9</td>
<td>386 ± 10</td>
<td>372 ± 11</td>
</tr>
<tr>
<td>Blood glucose (mM)</td>
<td>6.2 ± 0.1</td>
<td>6.1 ± 0.1</td>
<td>6.5 ± 0.1</td>
<td>23.4 ± 1.2*</td>
<td>22.8 ± 0.7*</td>
<td>20.0 ± 0.1*</td>
</tr>
<tr>
<td>MNCV (m/sec)</td>
<td>56.9 ± 1.1</td>
<td>55.3 ± 1.1</td>
<td>57.1 ± 1.0</td>
<td>45.5 ± 1.2*</td>
<td>54.1 ± 0.8**</td>
<td>53.7 ± 1.3*</td>
</tr>
<tr>
<td>SNCV (m/sec)</td>
<td>45.9 ± 0.9</td>
<td>45.5 ± 0.9</td>
<td>43.7 ± 0.9</td>
<td>35.9 ± 1.2*</td>
<td>37.0 ± 0.8*</td>
<td>41.2 ± 0.4*</td>
</tr>
<tr>
<td>Thermal response latency (sec)</td>
<td>10.9 ± 0.4</td>
<td>11.4 ± 0.6</td>
<td>11.8 ± 0.7</td>
<td>18.5 ± 0.6*</td>
<td>16.9 ± 0.7*</td>
<td>12.9 ± 0.5*</td>
</tr>
<tr>
<td>Tactile response threshold (g)</td>
<td>20.8 ± 1.2</td>
<td>22.0 ± 1.1</td>
<td>18.7 ± 1.2</td>
<td>6.5 ± 0.7*</td>
<td>7.8 ± 0.3*</td>
<td>13.0 ± 1.6*</td>
</tr>
</tbody>
</table>

Zucker diabetic fatty (ZDF) rats and age matched ZDF lean (control) rats at 15 weeks of age were treated for 4 weeks with two doses of cariporide (10 or 20 mg/kg/day). The initial weight for lean and ZDF rats at 15 weeks of age was 343 ± 3 and 374 ± 6*, respectively. Data are presented as the mean ± SEM. *p < 0.05 compared to control, †p < 0.05 compared to untreated diabetic. Number in parentheses indicates the number of experimental animals.

Table 3. 4-hydroxynonenal adduct and nitrotyrosine concentrations in the sciatic nerve in lean and ZDF rats treated with or without cariporide for 4 weeks.

<table>
<thead>
<tr>
<th>Determination</th>
<th>Control (10)</th>
<th>Control + cariporide (10)</th>
<th>ZDF (10)</th>
<th>ZDF + cariporide (10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-Hydroxynonenal adducts (pmol/mg protein)</td>
<td>26.8 ± 2.0</td>
<td>26.5 ± 2.3</td>
<td>32.4 ± 1.9*</td>
<td>26.2 ± 1.1*</td>
</tr>
<tr>
<td>Nitrotyrosine (pmol/mg protein)</td>
<td>39.2 ± 6.2</td>
<td>31.3 ± 4.3</td>
<td>167.9 ± 25.3*</td>
<td>105.3 ± 12.4*</td>
</tr>
</tbody>
</table>

Zucker diabetic fatty (ZDF) rats and age matched ZDF lean (control) rats at 15 weeks of age were treated for 4 weeks with cariporide (20 mg/kg/day). Data are presented as the mean ± SEM. *p < 0.05 compared to control, †p < 0.05 compared to untreated diabetic. Number in parentheses indicates the number of experimental animals.

Figure 1. (left) Representative images of intraepidermal nerve fiber profiles, magnification x 400. (right) Intraepidermal nerve fiber densities in lean ZDF rats (ZDF L) and ZDF diabetic (ZDF D) rats at 19 weeks of age maintained with or without 20 mg/kg/day cariporide (CP) treatment for 4 weeks at 15 weeks of age. Mean ± SEM, n = 10 per group. **p < 0.01 vs. ZDF lean rats, †p < 0.01 vs. untreated ZDF diabetic rats.

4-hydroxynonenal adducts and nitrotyrosine levels are significantly increased in the sciatic nerve of ZDF rats and that these markers of oxidative and nitrosative stress are improved with cariporide treatment (20 mg/kg/day) for 4 weeks. Treatment of lean rats with cariporide for 4 weeks did not affect the presence of these pathological markers in the sciatic nerve.

Effect of treatment of ZDF rats with cariporide on expression of Na+/H+-exchanger-1 and nitrated proteins in dorsal root ganglion neurons. In this study, we determined if Na+/H+-exchanger-1 overexpression occurs in dorsal root ganglion neurons and whether it is related to oxidative-nitrosative stress. ZDF rats were treated with the Na+/H+-exchanger-1 inhibitor cariporide at the dose of 20 mg/kg/d for 4 weeks after 15 weeks of age. Expression of Na+/H+-exchanger-1 is increased in dorsal root ganglion neurons from untreated diabetic rats compared to neurons from lean rats and after 4 weeks of treatment with cariporide the expression of Na+/H+-exchanger-1 remained significantly higher and was not significantly different compared to untreated ZDF rats (Figure 3). Nitrotyrosine fluorescence was increased in dorsal root ganglion neurons of untreated ZDF rats, indicative of neuronal oxidative-nitrosative stress (Figure 4). Treating ZDF rats with cariporide significantly decreased

Figure 2. (left) Representative Western blot and (right) analysis by densitometry of rat sciatic nerve of expression of methylglyoxal-derived AGE. Lean ZDF rats (ZDF L) and ZDF diabetic (ZDF D) rats at 19 weeks of age maintained with or without 20 mg/kg/day cariporide (CP) treatment for 4 weeks at 15 weeks of age. Control was arbitrarily assigned a value of 100%. Mean ± SEM, n = 10 per group. **p < 0.01 vs. ZDF lean rats, †p < 0.05 vs. untreated ZDF diabetic rats.

Copyright © 2014 SciRes.
One limitation using the ZDF Type 2 diabetic model is the restriction of the studies to male rats. This can raise the issue of translational significance when limiting studies to only one gender. Previously we demonstrated that the development of diabetic neuropathy in ZDF rats was progressive and a difficult condition to reverse [29,30]. We found that treating ZDF rats with different classes of drugs including enalapril, an angiotensin converting enzyme inhibitor, α-lipoic acid, an antioxidant, rosuvastatin, an HMG-CoA reductase inhibitor, or rosiglitazone, a thiazolidinedione which binds to and activates the peroxisome proliferator-activated receptors-γ only partially improved diabetic neuropathy [30]. A common mechanism of interaction for these drugs was to reduce oxidative and inflammatory stress [30]. With cariporide we found that it also reduced oxidative and nitrosative stress in Type 1 diabetic rats but it was unknown what efficacy it may have in a Type 2 diabetic rat model [10].

The Na+/H+-exchanger-1 isoform is found in the plasma membrane of most mammalian cells and is normally described as the housekeeping isoform [22]. Na+/H+-exchanger-1 plays a critical role in intracellular pH and cell volume homeostasis and regulates a number of cell behaviors, including adhesion, shape determination, migration, and proliferation [14,31]. Another important function of Na+/H+-exchanger-1 is regulation of glycolysis. Activation of Na+/H+-exchanger-1 causes cytosol alkalization and activation of glycolysis. Recently, a Na+/H+-exchange dependent increase of intracellular pH by ~0.3 units was found to cause a one order magnitude increase in the rate of glycolysis [32-35]. It is well known that upregulation of glycolysis contributes to the formation of by-products of glycolysis i.e., methylglyoxal, α-glycerophosphate, and diacylglycerol, with concomitant activation of advanced glycation end-product formation, which has been associated with the development of diabetes complications including diabetic neuropathy [36,37].

Hyperglycemia is associated with stimulation of Na+/H+-exchanger-1 [22,38]. In the diabetic kidney it has been demonstrated that Na+/H+-exchanger-3 activity is increased [22]. We have shown that in the sciatic nerve and dorsal root ganglion Type 1 diabetes increases the expression of Na+/H+-exchanger-1 and in this study we demonstrated that Na+/H+-exchanger-1 expression is increased in the dorsal root ganglion neurons from a Type 2 diabetic rat model [10]. Hyperglycemia and oxidative stress both stimulate Na+/H+-exchanger-3 activity via angiotensin II receptor activation [22]. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers reduce progression of diabetic nephropathy and we have shown that these drugs also improve diabetic neuropathy [27,39-42]. It is unknown if angiotensin converting enzyme inhibitors or angiotensin re-
ceptor blockers decrease \( \text{Na}^+/\text{H}^+\)-exchanger-1 activity in diabetes. However, these data imply that one possible mechanism for the beneficial effects of angiotensin converting enzyme inhibitors or angiotensin receptor blockers on diabetic complications including neuropathy may be through inhibiting the activation of \( \text{Na}^+/\text{H}^+\)-exchangers.

Hyperglycemia and increased metabolic rate could accentuate proton production and lead to increased proton efflux through \( \text{Na}^+/\text{H}^+\) exchange, which would stimulate \( \text{Na}^+/\text{Ca}^{2+} \) exchange and calcium overload [38]. Imbalance of sodium and calcium with hyperglycemia is associated with endothelial dysfunction and apoptosis [38], proliferation of vascular smooth muscle cells [43], retinal microangiopathy and ischemic damage [18,44], and myocardial damage [45-47]. It has been shown that inhibition of \( \text{Na}^+/\text{H}^+\)-exchanger-1 yields beneficial effects on diabetes vascular, retinal and renal complications but until our studies no information was available whether inhibiting \( \text{Na}^+/\text{H}^+\)-exchanger-1 improves diabetic peripheral neuropathy [10,18,22].

In this study we demonstrated that after about 7 - 8 weeks of hyperglycemia expression of \( \text{Na}^+/\text{H}^+\)-exchanger-1 was increased in dorsal root ganglion neurons from ZDF rats and that subsequent cariporide treatment for 4 weeks improved neural defects of diabetic neuropathy including nerve conduction velocity, thermal and tactile sensitivity and regeneration of intraepidermal nerve fibers without reducing the expression of \( \text{Na}^+/\text{H}^+\)-exchanger-1 in dorsal root ganglion neurons. Improvement in diabetic neuropathy endpoints with cariporide treatment was associated with reduction of oxidative stress in sciatic nerve and dorsal root ganglion neurons and reduction of a marker of advanced glycation end-product in sciatic nerve. Overall, the results from this study were similar to the results we obtained treating Type 1 diabetic rats with cariporide except for the concentration required to achieve a significant improvement in diabetic neuropathy endpoints [10]. In our studies with Type 1 diabetic rats of a longer duration of hyperglycemia than in these studies treating diabetic rats for four weeks with 10 mg/kg/rat cariporide was sufficient to achieve a significant improvement in diabetic neuropathy [10]. However, in these studies treating ZDF rats with 10 mg/kg/rat cariporide for four weeks after 7 - 8 weeks of untreated diabetes had little to no effect on improving diabetic neuropathy. A higher dose of cariporide, 20 mg/kg/day, was required to achieve a similar improvement in diabetic neuropathy in Type 2 diabetic rats compared to a Type 1 diabetic rat model. This supports our previous findings that reversal of diabetic neuropathy is more difficult in Type 2 diabetes. This would suggest that early intervention and more aggressive therapy may be needed for treatment of diabetic neuropathy in Type 2 diabetic patients.

In summary, it is widely believed that oxidative stress plays an important role in the pathogenesis of peripheral diabetic neuropathy and that several pathways activated by hyperglycemia contribute to the generation of reactive oxygen/nitrogen species. We have shown that \( \text{Na}^+/\text{H}^+\)-exchanger-1 is overexpressed in peripheral nerve and contributes to the accumulation of markers for oxidative/nitrosative stress and advanced glycation end-products [10]. Inhibiting \( \text{Na}^+/\text{H}^+\)-exchanger-1 in Type 1 and Type 2 diabetic rats reduced the levels of these markers in nerve and improved diabetic neuropathy [10]. These studies provide rationale for further development of \( \text{Na}^+/\text{H}^+\)-exchanger-1 inhibitors for treatment of diabetic neural complications.

ACKNOWLEDGEMENTS

This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development (BX001680-01, MAY), by National Institute of Diabetes and Digestive and Kidney Diseases Grant DK073990 (MAY) and DK077141 (IGO and MAY) from NIH. The content of this manuscript are new and solely the responsibility of the authors and do not necessarily represent the official views of the granting agencies.

REFERENCES


http://dx.doi.org/10.1042/BST0311358

http://dx.doi.org/10.1016/s0005-2728(03)00125-0


http://dx.doi.org/10.1152/ajpendo.00186.2013

http://dx.doi.org/10.1016/j.neuroscience.2011.09.038

http://dx.doi.org/10.1189/jlb.0406262

http://dx.doi.org/10.1007/s10521-012-9856-9

http://dx.doi.org/10.1139/y04-119

http://dx.doi.org/10.1007/s00232-002-1030-8

http://dx.doi.org/10.2174/1568060654553417

http://dx.doi.org/10.1023/A:1010867631953


http://dx.doi.org/10.1023/A:1021643608619

http://dx.doi.org/10.1016/j.neures.2005.09.003

http://dx.doi.org/10.1023/A:1006891007014

http://dx.doi.org/10.1016/j.bbrc.2012.09.050

http://dx.doi.org/10.1093/cvr/cvn179

http://dx.doi.org/10.2337/diabetes.54.1.1234

http://dx.doi.org/10.1016/j.ejphar.2007.05.055

http://dx.doi.org/10.1016/j.expneurol.2011.04.002

http://dx.doi.org/10.1023/A:1010867631953


